Overview
Phosphoserine aminotransferase (PSAT) deficiency, infantile/juvenile form, is an extremely rare inherited metabolic disorder that affects the body's ability to make the amino acid L-serine. L-serine is essential for many important processes in the body, including brain development, nerve function, and the production of other important molecules. The disease is caused by mutations in the PSAT1 gene, which provides instructions for making an enzyme needed in one of the key steps of serine production. In the infantile and juvenile forms, children may present with seizures, intellectual disability, and delayed development that become apparent in infancy or childhood. Some children also experience a smaller-than-expected head size (microcephaly) and problems with movement and coordination. The severity of symptoms can vary, but neurological problems are typically the most prominent feature. Treatment involves supplementation with L-serine, and sometimes glycine, to restore the amino acids the body cannot produce on its own. When started early, treatment may help improve seizure control and support better developmental outcomes, though the degree of improvement depends on how early treatment begins and the severity of the condition. Because this disease is so rare, awareness among healthcare providers is limited, which can lead to delays in diagnosis.
Also known as:
Key symptoms:
Seizures that may be difficult to controlIntellectual disabilityDelayed development of motor skills like sitting and walkingSmaller than expected head size (microcephaly)Delayed speech and language developmentLow muscle tone (floppiness)Difficulty with coordination and balanceBehavioral difficultiesFeeding problems in infancyFailure to thrive or poor growthIrritabilityProblems with attention and learning
Clinical phenotype terms (40)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Phosphoserine aminotransferase deficiency, infantile/juvenile form.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Phosphoserine aminotransferase deficiency, infantile/juvenile form at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Phosphoserine aminotransferase deficiency, infantile/juvenile form.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Phosphoserine aminotransferase deficiency, infantile/juvenile form.
Community
No community posts yet. Be the first to share your experience with Phosphoserine aminotransferase deficiency, infantile/juvenile form.
Start the conversation →Latest news about Phosphoserine aminotransferase deficiency, infantile/juvenile form
No recent news articles for Phosphoserine aminotransferase deficiency, infantile/juvenile form.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the recommended dose of L-serine for my child, and how often should it be given?,Should my child also take glycine supplements?,How often should amino acid levels in the blood or spinal fluid be checked?,What seizure medications work best alongside L-serine supplementation?,What developmental therapies do you recommend, and how often?,Are there any clinical trials or new treatments being studied for this condition?,Should other family members be tested for carrier status?
Common questions about Phosphoserine aminotransferase deficiency, infantile/juvenile form
What is Phosphoserine aminotransferase deficiency, infantile/juvenile form?
Phosphoserine aminotransferase (PSAT) deficiency, infantile/juvenile form, is an extremely rare inherited metabolic disorder that affects the body's ability to make the amino acid L-serine. L-serine is essential for many important processes in the body, including brain development, nerve function, and the production of other important molecules. The disease is caused by mutations in the PSAT1 gene, which provides instructions for making an enzyme needed in one of the key steps of serine production. In the infantile and juvenile forms, children may present with seizures, intellectual disabilit
How is Phosphoserine aminotransferase deficiency, infantile/juvenile form inherited?
Phosphoserine aminotransferase deficiency, infantile/juvenile form follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.